Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients with No Progression and with No More than Five Residual Metastatic Lesions Following First-Line Systemic Therapy: A Retrospective Analysis
Authors:
- Amélie AboudaramAAAmélie Aboudaram
- Léonor ChaltielLCLéonor Chaltiel
- Damien PouesselDPDamien Pouessel
- Pierre Graff-CailleaudPGPierre Graff-Cailleaud
- Nicolas Benziane-OuaritiniNBNicolas Benziane-Ouaritini
- Paul SargosPSPaul Sargos
- Ulrike SchickUSUlrike Schick
- Gilles CréhangeGCGilles Créhange
- Elizabeth Cohen-Jonathan MoyalEMElizabeth Cohen-Jonathan Moyal
- Christine ChevreauCCChristine Chevreau
- Jonathan KhalifaJKJonathan Khalifa
Open Access
Abstract
Local consolidative radiotherapy in the treatment of metastatic malignancies has shown promising results in several types of tumors. The objective of this study was to assess consolidative radiotherapy to the bladder and to residual metastases in metastatic urothelial bladder cancer with no progression following first-line systemic therapy. Materials/methods: Patients who received first-line therapy for the treatment of metastatic urothelial bladder cancer (mUBC) and who were progression-free following treatment with no more than five residual metastases were retrospectively identified through the database of four Comprehensive Cancer Centers, between January 2005 and December 2018. Among them, patients who received subsequent definitive radiotherapy (of EQD2Gy > 45Gy) to the bladder and residual metastases were included in the consolidative group (irradiated (IR) group), and the other patients were included in the observation group (NIR group). Progression-free survival (PFS) and overall survival (OS) were determined from the start of the first-line chemotherapy using the Kaplan–Meier method. To prevent immortal time bias, a Cox model with time-dependent covariates and 6-month landmark analyses were performed to examine OS and PFS. Results: A total of 91 patients with at least stable disease following first-line therapy and with no more than five residual metastases were analyzed: 51 in the IR group and 40 in the NIR group. Metachronous metastatic disease was more frequent in the NIR group (19% vs. 5%, p = 0.02); the median number of metastases in the IR group vs. in the NIR group was 2 (1–9) vs. 3 (1–5) (p = 0.04) at metastatic presentation, and 1 (0–5) vs. 2 (0–5) (p = 0.18) after completion of chemotherapy (residual lesions), respectively. Two grade 3 toxicities (3.9%) and no grade 4 toxicity were reported in the IR group related to radiotherapy. With a median follow up of 85.9 months (95% IC (36.7; 101.6)), median OS and PFS were 21.7 months (95% IC (17.1; 29.7)) and 11.1 months (95% IC (9.9; 14.1)) for the whole cohort, respectively. In multivariable analysis, consolidative radiotherapy conferred a benefit in both PFS (HR = 0.49, p = 0.007) and OS (HR = 0.47, p = 0.015) in the whole population; in the landmark analysis at 6 months, radiotherapy was associated with improved OS (HR = 0.48, p = 0.026), with a trend for PFS (HR = 0.57, p = 0.082). Conclusion: Consolidative radiotherapy for mUBC patients who have not progressed after first-line therapy and with limited residual disease seems to confer both OS and PFS benefits. The role of consolidative radiotherapy in the context of avelumab maintenance should be addressed prospectively.Keywords
This publication has 54 references indexed in Scilit:
- Result of Surgical Resection for Pulmonary Metastasis from Urothelial CarcinomaThe Korean Journal of Thoracic and Cardiovascular Surgery, 2012
- Immortal Time Bias: A Frequently Unrecognized Threat to Validity in the Evaluation of Postoperative RadiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Could salvage surgery after chemotherapy have clinical impact on cancer survival of patients with metastatic urothelial carcinoma?International Journal of Clinical Oncology, 2011
- Surgery for Metastatic Urothelial Carcinoma with Curative Intent: The German Experience (AUO AB 30/05)European Urology, 2009
- Long-term survival after combined modality treatment in metastatic bladder cancer patients presenting with supra-regional tumor positive lymph nodes onlyEuropean Journal of Surgical Oncology, 2009
- Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapyJournal of Experimental Medicine, 2006
- Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumoursEuropean Journal of Cancer, 2006
- Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder CancerJournal of Clinical Oncology, 2005
- Is There a Role for Surgery in the Management of Metastatic Urothelial Cancer? The M. D. Anderson ExperienceJournal of Urology, 2004
- Is There a Therapeutic Role for Post-Chemotherapy Retroperitoneal Lymph Node Dissection in Metastatic Transitional Cell Carcinoma of the Bladder?Journal of Urology, 2003